Abstracts

Ipsen announces clinical data to be presented at ISPRM demonstrating commitment to neurotoxin research and support for patients and the neuroscience community

09th July
2018

Abstract ISPR8-1217 – A7.02 Rehabilitation Addressing Specific Issues – Spasticity Management

Monday 09th July to Thursday 12th July
Exhibition Area

Impact of Spasticity and Botulinum Toxin-A Injections on the Daily Life of Patients’ and their Caregivers’: Results from an International Online Survey

First author: Manuel Murie Fernandez

09th July
2018

Abstract ISPR8-2146 – D3.03 Education and Training in Rehabilitation – Continuous Medical Education and Professional Development

Monday 09th July to Thursday 12th July
Exhibition Area

Botulinum Neurotoxin-A Usage and Training in Cervical Dystonia & Spastic Paresis: First Results from the Ixcellence® Network Survey

First author: Luis Jorge Jacinto

09th July
2018

Abstract ISPR8-2147 – D3.03 Education and Training in Rehabilitation – Continuous Medical Education and Professional Development

Monday 09th July to Thursday 12th July
Exhibition Area

Improving Management Practices of Cervical Dystonia and Spastic Paresis: 5 Years’ Experience of Ixcellence® Network, an Innovative International Educational Program

First author: Luis Jorge Jacinto

09th July
2018

bstract ISPR8-2514 – A7.02 Rehabilitation Addressing to Specific Issues – Spasticity Management

Monday 09th July to Thursday 12th July
Exhibition Area

Simultaneous Upper and Lower Limb AbobotulinumtoxinA Injections and Guided Self-Rehabilitation Contracts in Spastic Hemiparesis: Baseline Data from the ENGAGE Study

First author: Jean-Michel Gracies

09th July
2018

Abstract ISPR8-2521 – A7.02 Rehabilitation Addressing to Specific Issues – Spasticity Management

Monday 09th July to Thursday 12th July
Exhibition Area

Repeated AbobotulinumtoxinA Injections Benefit Walking Speed, Step Length and Cadence in Adults with Spastic Hemiparesis due to Stroke or Traumatic Brain Injury

First author: Alberto Esquenazi

09th July
2018

Abstract ISPR8-2529 – A7.02 Rehabilitation Addressing to Specific Issues – Spasticity Management

Monday 09th July to Thursday 12th July
Exhibition Area

Efficacy and Safety of Early Use of AbobotulinumtoxinA in Adults with Post-Stroke Spasticity: Results from the ONTIME and ABCDE-S Studies

First author: Raymond Rosales

09th July
2018

Abstract ISPR8-2543 – A7.02 Rehabilitation Addressing to Specific Issues – Spasticity Management

Monday 09th July to Thursday 12th July
Exhibition Area

Treatment Frequency for Long-Term Efficacy of AbobotulinumtoxinA Injections: a Phase 3 Study in Patients with Upper Limb Spasticity Following Stroke or Traumatic Brain Injury

First author: Jean-Michel Gracies

09th July
2018

Abstract ISPR8-2546 – A7.02 Rehabilitation Addressing to Specific Issues – Spasticity Management

Monday 09th July to Thursday 12th July
Exhibition Area

When Can Maximal Efficacy be Expected with Repeated Botulinum Toxin Injections in Upper Limb Spastic Paresis? An Exploratory Statistical Analysis

First author: Jean-Michel Gracies

09th July
2018

Abstract ISPR8-2547 – A7.02 Rehabilitation Addressing to Specific Issues – Spasticity Management

Monday 09th July to Thursday 12th July
Exhibition Area

AbobotulinumtoxinA Injections in Shoulder Muscles: Results from a Real World (ULIS-II) and Phase 3 (AUL) Studies

First author: Francois Constant Boyer

09th July
2018

ISPR8-2557 – A7.02 Rehabilitation Addressing to Specific Issues – Spasticity Management

Monday 09th July to Thursday 12th July
Exhibition Area

Treatment Frequency for Long-Term Efficacy of AbobotulinumtoxinA Injections: a Phase 3 Study in Patients with Lower Limb Spasticity Following Stroke or Traumatic Brain Injury

First author: Prof Jean-Michel Gracies

09th July
2018

Abstract ISPR8-2654 – A2.08 Musculoskeletal Conditions – Miscellanous, Exhibition Area,

Monday 09th July to Thursday 12th July
Exhibition Area

Results from the First Recombinant Botulinum Toxin (BoNT) Ever to Enter Clinical Development. Outcomes of a First-in-Human Study with Recombinant BoNT/E (SXN102308)

First author: Laurent Pons